Jonathan Druge
Global Product Manager, Miltenyi Biotec
Jonathan Druge joined Miltenyi Biotec in 2019 to pursue his doctoral studies in immuno-oncology, as part of the network “Manufacturing tumor-reactive Natural Killer cells” (MATURE-NK) project, a European Union-funded consortium run by the Marie Skłodowska Curie Action program. While under the academic supervision of Ulrike Köhl and Adelheid Cerwenka, two leading experts in the field of NK cells, Jonathan focused on developing next-generation CAR NK cells. After the successful completion of the experimental part of his PhD, he joined the Miltenyi Biotec Marketing Department in 2022, specializing in research applications related to cell and gene therapies in immuno-oncology.
Latest Content
Webinar
Unlock the Full Potential of Your CAR NK Cells
Natural killer (NK) cells are a promising tool in the fight against cancer. Engineering them with chimeric antigen receptors (CARs) further bolsters their specific anti-tumor activity.
Webinar
Unlock the Full Potential of Your CAR NK Cells
Natural killer (NK) cells are a promising tool in the fight against cancer. Engineering them with chimeric antigen receptors (CARs) further bolsters their specific anti-tumor activity.
Advertisement
